Drug Profile
Research programme: eye disorders therapy - Alcon/Origenis
Alternative Names: MOREsystem®Latest Information Update: 15 Apr 2019
Price :
$50
*
At a glance
- Originator Alcon
- Developer Alcon; Origenis
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon
- 17 Oct 2008 Preclinical development is ongoing USA and Germany
- 15 Oct 2008 Alcon Research and Origenis extend their research alliance for the treatment of eye disorders